38.98
-0.78 (-1.96%)
| Penutupan Terdahulu | 39.76 |
| Buka | 39.76 |
| Jumlah Dagangan | 2,986,819 |
| Purata Dagangan (3B) | 3,054,925 |
| Modal Pasaran | 5,983,646,720 |
| Harga / Buku (P/B) | 30.88 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| EPS Cair (TTM) | -1.97 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.80% |
| Nisbah Semasa (MRQ) | 5.13 |
| Aliran Tunai Operasi (OCF TTM) | -221.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -125.17 M |
| Pulangan Atas Aset (ROA TTM) | -47.45% |
| Pulangan Atas Ekuiti (ROE TTM) | -84.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Cogent Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.00 |
|
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.04% |
| % Dimiliki oleh Institusi | 103.39% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (HC Wainwright & Co., 28.27%) | Beli |
| 50.00 (Leerink Partners, 28.27%) | Beli | |
| Median | 44.00 (12.88%) | |
| Rendah | 16.00 (Stifel, -58.95%) | Pegang |
| Purata | 38.80 (-0.46%) | |
| Jumlah | 3 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 26.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2025 | 50.00 (28.27%) | Beli | 33.83 |
| 04 Nov 2025 | 21.00 (-46.13%) | Beli | 14.13 | |
| Baird | 11 Nov 2025 | 34.00 (-12.78%) | Pegang | 33.42 |
| Leerink Partners | 10 Nov 2025 | 50.00 (28.27%) | Beli | 32.46 |
| JP Morgan | 21 Oct 2025 | 44.00 (12.88%) | Beli | 15.86 |
| Stifel | 16 Oct 2025 | 16.00 (-58.95%) | Pegang | 16.36 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |